1-3 of 3
James Drew
Close
Save search
Sort by
Journal Articles

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study

Free
Catherine Thieblemont, Javier Munoz, Alessandra Tucci, Carlo Visco, Guillaume Cartron, Paolo Corradini, Ian W. Flinn, Thomas Gastinne, Kamal Krimo Bouabdallah,, Luca Arcaini, Grzegorz S. Nowakowski, Louise Roulin, Max Topp, Shekeab Jauhari, Vladan Vucinic, Peter Martin, Argyrios Gkasiamis, James Drew, Parth Rao, Mark Kaplan, Yiming Cheng, Ju Li, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 569–572.
https://doi.org/10.1182/blood-2022-162559
Published: 2022
Journal Articles

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Open Access
Clinical Trials & Observations
Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria V. Revuelta, Leandro Cerchietti, John P. Leonard
Journal: Blood
Blood (2022) 139 (8): 1147–1159.
https://doi.org/10.1182/blood.2021011679
Published: 2022
Includes: Supplemental data
Journal Articles

Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)

Free
Peter Martin, FRCPC, MD MS, Nancy L. Bartlett, MD, Julio C. Chavez, MD, John L. Reagan, MD, Sonali M. Smith, MD, Ann S. LaCasce, MD MSc, Jeffrey A. Jones, MD MPH, James Drew, MA, Chengqing Wu, PhD, Leandro Cerchietti, MD, John P. Leonard, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2964.
https://doi.org/10.1182/blood-2018-99-114438
Published: 2018